Polyclonal Antibody Stimulator (PAS) is a fusion peptide being developed for the treatment
of gastrointestinal cancers, metastatic gastrinoma, and colorectal adenoma.
Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire all the technology and intellectual property for a product that inhibits the hormone gastrin. This recently acquired broad intellectual property portfolio includes composition and use-protection for a lead compound, PAS, that has been clinically studied in three gastrointestinal cancers.
The company has developed an intellectual property strategy that holds over 100 United States and worldwide patents related to PAS. In addition, Cancer Advances has a trademark portfolio and strategy for pursuing other trademarks.
Few products are currently in late-stage clinical development for the treatment of gastric and pancreatic cancer. Because there remains a significant unmet medical need, a wide variety of immunomodulators are being developed including cytokines, adaptive T-cells, therapeutic vaccines, and monoclonal antibodies; PAS falls under the broad category of therapeutics known as immunomodulators. PAS functions by stimulating the immune system in the recipient to produce endogenous polyclonal antibodies to gastrin without the risks and limitations associated with serum-derived polyclonal treatment or monoclonal antibody therapy.